ESSENTIAL THROMBOCYTOSIS

Clinical trials for ESSENTIAL THROMBOCYTOSIS explained in plain language.

Never miss a new study

Get alerted when new ESSENTIAL THROMBOCYTOSIS trials appear

Sign up with your email to follow new studies for ESSENTIAL THROMBOCYTOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New pill targets tough blood cancers in major trial

Disease control Completed

This study tested a new oral drug called pelabresib for people with advanced blood cancers like myelofibrosis. The first part aimed to find a safe dose. The second part tested if pelabresib, given alone or with another drug (ruxolitinib), could shrink enlarged spleens, reduce the…

Matched conditions: ESSENTIAL THROMBOCYTOSIS

Phase: PHASE1, PHASE2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control

Last updated Mar 30, 2026 14:34 UTC

ESSENTIAL THROMBOCYTOSIS

Get alerted when new ESSENTIAL THROMBOCYTOSIS trials appear

New pill targets tough blood cancers in major trial